| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion |
| 29 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 27, 2026, at a meeting of the Board of Directors (the “Board”) of Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”), the Board elected Dr. David J. Brailer to serve as a member of the Board, effective November 3, 2... |
| 16 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
Creating the series of Securities (as defined herein) designated |
| 14 Sep 2026 |
8-K: Other Events
On September 14, 2026, Teva Pharmaceutical Industries Ltd. (the “Company”) began trading its ordinary shares on the New York Stock Exchange, in lieu of its American depositary shares (“ADSs”), under the same ticker symbol under which the... |
| 11 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
To: the other Euro Underwriters (as defined herein) listed in Part A of Schedule I hereto; |
| 03 Sep 2026 |
8-K: Other Events
Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) is filing this Exhibit 99.1 to recast historical segment information as set forth in the Company’s Annual Report on Form |
| 03 Sep 2026 |
8-K: Material Modification to Rights of Security Holders
AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED DEPOSIT AGREEMENT, dated as of August 31, 2026 (“Amendment No. 1”), by and among Teva Pharmaceutical Industries Limited, a company incorporated under the laws of the State of Israel, and its... |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy |
| 28 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) held its Annual Meeting on May 28, 2026 (the “Annual Meeting”). The following is a summary of the matters voted on at the meeting. |
| 29 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
For an accessible version of this Press Release, please visit www.tevapharm.com |
| 28 Jan 2026 |
8-K: Results of Operations and Financial Condition
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation |
| 11 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
This AMENDMENT to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, dated as of December 10, 2025 (this “Amendment”), is made and entered into by and among TEVA PHARMACEUTICAL INDUSTRIES LIMITED, an Israeli company r... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS |
| 30 Jul 2025 |
8-K: Results of Operations and Financial Condition
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components |
| 05 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) held its Annual Meeting on June 5, 2025 (the “Annual Meeting”). The following is a summary of the matters voted on at the meeting. |
| 28 May 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
THIS INDENTURE, dated as of May 28, 2025, by and among Teva Pharmaceutical Finance Netherlands IV B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid), incorporated under Dutch law (the “I... |
| 22 May 2025 |
8-K: Regulation FD Disclosure; Other Events
To: the other Euro Underwriters (as defined herein) listed in Part A of Schedule I hereto |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved |
| 29 Jan 2025 |
8-K: Results of Operations and Financial Condition
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth |
Loading...